Robert W. Baird initiated coverage on Merit Medical with a new price target
$MMSI
Medical/Dental Instruments
Health Care
Robert W. Baird initiated coverage of Merit Medical with a rating of Outperform and set a new price target of $96.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/26/2026 | $78.00 | Overweight → Equal Weight | Wells Fargo |
| 2/6/2026 | $107.00 | Buy | BTIG Research |
| 3/28/2025 | $120.00 | Overweight | Analyst |
| 12/11/2024 | $103.00 → $120.00 | Equal Weight → Overweight | Wells Fargo |
| 6/28/2024 | $96.00 | Outperform | Robert W. Baird |
| 4/11/2024 | $88.00 | Buy | CL King |
| 2/7/2024 | $87.00 | Neutral | BofA Securities |
| 12/21/2023 | $100.00 | Hold → Buy | Canaccord Genuity |
Wells Fargo downgraded Merit Medical from Overweight to Equal Weight and set a new price target of $78.00
BTIG Research initiated coverage of Merit Medical with a rating of Buy and set a new price target of $107.00
Analyst initiated coverage of Merit Medical with a rating of Overweight and set a new price target of $120.00
SOUTH JORDAN, Utah, May 19, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of healthcare technology, today announced that shareholders elected Scott R. Ward to the company's Board of Directors at Merit's annual meeting of shareholders. Mr. Ward was elected to serve a three-year term. "On behalf of the Board, we are pleased with Scott Ward's election to Merit's Board of Directors," said F. Ann Millner, Merit's Chair of the Board. "Scott's extensive industry experience, strategic insight, and commitment to innovation will be tremendous assets as we continue advancing the company's strategic priorities." "We are proud to welco
SOUTH JORDAN, Utah, May 08, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of healthcare technology, today announced that Merit management will participate in the Bank of America 2026 Health Care Conference, to be held in Las Vegas, Nevada, May 12-14, 2026. The management team will participate in a fireside chat session on Tuesday, May 12th at 3:00 pm Pacific Time / 6:00 pm Eastern Time. A live audio webcast of the fireside chat will be accessible under the "Events" section of the Company's investor relations website at Investor Events and Presentations - Merit Medical. A replay of the fireside chat will be available on this
Financial Highlights† Reported revenue of $381.9 million, up 7%Constant currency revenue* and constant currency revenue, organic* up 5% and up 3%, respectively Constant currency revenue, organic* increased 4%, excluding revenue from divested product line GAAP operating margin of 11.6%, compared to 11.5% in prior year periodNon-GAAP operating margin* of 19.7%, compared to 19.3% in prior year periodGAAP EPS $0.68, up 39%Non-GAAP EPS* $0.94, up 9%Free cash flow* generation of $24.7 million, up 26% Business Developments On February 17, 2026, Merit sold certain assets related to the DualCap® product line to Health Line International Corporation for a purchase price of $28 million, of which $25
4 - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)
4 - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)
4 - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)
SD - MERIT MEDICAL SYSTEMS INC (0000856982) (Filer)
8-K - MERIT MEDICAL SYSTEMS INC (0000856982) (Filer)
S-8 - MERIT MEDICAL SYSTEMS INC (0000856982) (Filer)
4 - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)
4 - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)
4 - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)
For Immediate Release: June 14, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA issued a proposed exemption for certain cottage cheese products from the requirements of the Food Traceability Rule. The proposal would exempt Grade “A” cottage cheese that appears on the Interstate Milk Shippers List from the requirements of the r
SC 13G/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)
SC 13G/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)
SC 13G/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)
SOUTH JORDAN, Utah, May 19, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of healthcare technology, today announced that shareholders elected Scott R. Ward to the company's Board of Directors at Merit's annual meeting of shareholders. Mr. Ward was elected to serve a three-year term. "On behalf of the Board, we are pleased with Scott Ward's election to Merit's Board of Directors," said F. Ann Millner, Merit's Chair of the Board. "Scott's extensive industry experience, strategic insight, and commitment to innovation will be tremendous assets as we continue advancing the company's strategic priorities." "We are proud to welco
SOUTH JORDAN, Utah, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI) ("Merit" or the "Company"), a global leader of healthcare technology, today announced the resignation of its President, Joseph C. Wright, effective January 3, 2025. The Company noted that prior to Mr. Wright's resignation, Merit had received notice of allegations regarding his conduct, which Merit's independent directors investigated with the assistance of independent counsel. The allegations were unrelated to Merit's operations or financial performance. Based upon Mr. Wright's resignation, Merit's Board of Directors has re-appointed Fred P. Lampropoulos as Merit's President. ABOUT MERI
SOUTH JORDAN, Utah, May 16, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, today announced that its shareholders elected Silvia M. Perez, President of the Commercial Branding and Transportation Division at 3M Company, as a director in Merit's Annual Meeting of Shareholders held on May 15, 2024. Merit's shareholders also re-elected Fred P. Lampropoulos and Stephen C. Evans as directors. Ms. Perez and Messrs. Lampropoulos and Evans were elected to serve three-year terms. "We are pleased to welcome Silvia Perez as our newest director," said Mr. Lampropoulos, Merit's Chairman and Chief Executive Officer. "Her expertise and proven
Financial Highlights† Reported revenue of $381.9 million, up 7%Constant currency revenue* and constant currency revenue, organic* up 5% and up 3%, respectively Constant currency revenue, organic* increased 4%, excluding revenue from divested product line GAAP operating margin of 11.6%, compared to 11.5% in prior year periodNon-GAAP operating margin* of 19.7%, compared to 19.3% in prior year periodGAAP EPS $0.68, up 39%Non-GAAP EPS* $0.94, up 9%Free cash flow* generation of $24.7 million, up 26% Business Developments On February 17, 2026, Merit sold certain assets related to the DualCap® product line to Health Line International Corporation for a purchase price of $28 million, of which $25
SOUTH JORDAN, Utah, April 02, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, announced today that it will release its financial results for the quarter ended March 31, 2026, after the close of the stock market on Thursday, April 30, 2026. Merit plans to hold its investor conference call on the same day (Thursday, April 30, 2026) at 4:30 p.m. Eastern (3:30 p.m. Central, 2:30 p.m. Mountain, and 1:30 p.m. Pacific). To access the conference call, please pre-register using the following link. Registrants will receive confirmation with dial-in details. A live webcast and slide deck can be accessed using this link. A link to bo
SOUTH JORDAN, Utah, April 01, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, today announced it has acquired View Point Medical, Inc. (View Point). Through a merger transaction, View Point is now a wholly-owned subsidiary of Merit. View Point, located in Carlsbad, California, manufactures the OneMark® Detection Imaging System and OneMark Tissue Markers. The aggregate transaction consideration, including the assumption of ViewPoint liabilities, is approximately $140 million. Of that amount, $90 million was paid in cash at closing and two deferred payments of $25 million each are scheduled to be paid not later than the first and